RCG
ALNY icon

Rock Creek Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Rock Creek Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,196
Closed -$192K – 85
2018
Q3 		$192K Buy
+2,196
New +$221K 0.08% 82

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Rock Creek Group's ALNY Position: Q4 2018 in Review

Rock Creek Group sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2018, closing a stake of 2,196 shares — an estimated $192K sold.

Rock Creek Group first reported a position in ALNY in Q3 2018 and held it in 1 quarter. The position peaked at $192K in Q3 2018. 284 funds tracked by Wall St. Rank hold ALNY as of Q4 2018.

  • Rock Creek Group reported no remaining Alnylam Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Rock Creek Group sold 2,196 Alnylam Pharmaceuticals shares in Q4 2018, an estimated $192K.
  • Rock Creek Group first reported a position in Alnylam Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Rock Creek Group's Alnylam Pharmaceuticals position peaked at $192K in Q3 2018.
  • 284 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2018.

Based on Rock Creek Group's 13F filing for Q4 2018, filed 14 Feb 2019.